CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to ...

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

Trump told CNBC he will initially impose a “small tariff” on pharmas in the next week or so, but will raise it to 150% in a ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer raised its earnings outlook slightly when it reported second-quarter earnings on Aug. 5, 2025. Upcoming losses of ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Trump tweets trigger major stock swings for companies like Tesla, Boeing, Pfizer. Democrats demand an investigation.

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's ...